US › Healthcare

GRI Bio Inc. (GRI)

US · Healthcare · Biotechnology

$1.59+10.42%

Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue

Net profit

$-2.0M

Profit YoY

+34.4%

EPS

$-1.61

EPS estimate

$-3.74

EPS came in at -1.61 against a street estimate of -3.74 — a beat of 57.0%.

Key statistics

Market cap

$2.4M

P/E

0.0

Forward P/E

0.0

P/B

0.23

Book value

$6.65

EPS (TTM)

$38.89

52-week high

$80.36

52-week low

$1.36

50-day MA

$1.86

200-day MA

$13.35

Beta

-0.67

Analyst view

Analysts rate GRI Bio Inc. a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $21.00.

Shareholding

Insiders

0.46%

Institutions

2.80%

Largest institutional holders

Fund	Stake
Geode Capital Management, LLC	1.04%
UBS Group AG	0.49%
Tower Research Capital LLC	0.06%
BlackRock Inc	0.00%
SBI Securities Co Ltd	0.00%
Danske Bank A/S.	0.00%
Bank of America Corp	0.00%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for GRI Bio Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.